EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Live attenuated vaccination protects aged chimeric ACE2 mice from severe SARS-CoV-2 pathogenicity in vivo

Alina Russ, Vera Viherlehto, Stefanie Brey, Sabine Wittmann, Pascal Irrgang, Natascha Leicht, Arne Cordsmeier, Armin Ensser, Ralf J Rieker, Carol Geppert, Heinrich Sticht, Matthias Tenbusch und 2 weitere

PLOS Pathogens · 22.04.2026 · 22 (4) · e1014167

DOI: 10.1371/journal.ppat.1014167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 22.04.2026. Verfasst von Alina Russ und 13 weiteren Autor:innen. Beteiligte Einrichtung: Harald zur Hausen Institute of Virology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, COVID-19 Vaccines, Angiotensin-Converting Enzyme 2. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Medizinische Fakultät, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced age is one of the greatest risk factors for a severe outcome of COVID-19. Although mRNA vaccines were highly successful in protecting the elderly, the strongest increase in morbidity and mortality upon infection with emerging SARS-CoV-2 variants was among the elderly. To better understand SARS-CoV-2 pathogenicity and to thoroughly evaluate novel vaccination strategies, better models reliably reproducing human SARS-CoV-2 pathogenicity are needed. Here, we generated mice expressing a human-mouse chimera of ACE2 (chACE2) by CRISPR/Cas9-mediated gene editing in C57BL/6 mouse zygotes. ChACE2 mice express the chimeric viral receptor at physiological levels, enabling efficient SARS-CoV-2 infection without the heightened mortality seen in K18-hACE2 mice due to neuroinvasion. We used the chACE2 model to analyze SARS-CoV-2 infection as well as antiviral immune responses in vitro and in vivo. Similar to SARS-CoV-2 in elderly humans, aged chACE2 mice suffered from a highly aggravated disease. In addition, we found that a live attenuated vaccine candidate, LAV Nsp16 , induces robust mucosal and systemic immune responses in these mice despite being highly attenuated. The immunization with LAV Nsp16 protected aged chACE2 mice from otherwise severe pathogenicity of SARS-CoV-2 by blocking viral replication of homologous and heterologous SARS-CoV-2 variants. The newly developed chACE2 model allows for longer observation periods of SARS-CoV-2 infection in mice, which is essential for assessing the immunogenicity of novel vaccine designs or monitoring viral pathogenicity over time. Immunization with LAV Nsp16 induced robust and protective immune responses in young and aged mice, making viruses lacking 2’-O-methyltrasferse activity promising candidates for future live attenuated vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19COVID-19 VaccinesAngiotensin-Converting Enzyme 2AnimalsMiceVaccines, AttenuatedHumansMice, Inbred C57BLDisease Models, AnimalVaccinationMice, TransgenicFemale

Substanzen

COVID-19 VaccinesAngiotensin-Converting Enzyme 2Vaccines, AttenuatedAce2 protein, mouseACE2 protein, human

Autor:innen und Institutionen

  • Harald zur Hausen Institute of Virology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Department of Biology, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Institute of Pathology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Division of Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • FAU Profile Center Immunomedicine (FAU I-MED), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

ORCID-Profile: Thomas Gramberg

Förderung

  • Bundesministerium für Bildung und Forschung
  • Medizinische Fakultät, Friedrich-Alexander-Universität Erlangen-Nürnberg
  • Deutsche Forschungsgemeinschaft
  • Bayerisches Staatsministerium für Wissenschaft und Kunst

Zitieren

APA

Russ, A., Viherlehto, V., Brey, S., Wittmann, S., Irrgang, P., Leicht, N., Cordsmeier, A., Ensser, A., Rieker, R. J., Geppert, C., Sticht, H., Tenbusch, M., Winkler, T. H., & Gramberg, T. (2026). Live attenuated vaccination protects aged chimeric ACE2 mice from severe SARS-CoV-2 pathogenicity in vivo. PLOS Pathogens, 22(4), e1014167. https://doi.org/10.1371/journal.ppat.1014167

Vancouver

Russ A, Viherlehto V, Brey S, Wittmann S, Irrgang P, Leicht N, et al. Live attenuated vaccination protects aged chimeric ACE2 mice from severe SARS-CoV-2 pathogenicity in vivo. PLOS Pathogens. 2026;22(4):e1014167. doi:10.1371/journal.ppat.1014167

BibTeX
@article{Russ2026,
  author = {Russ, Alina and Viherlehto, Vera and Brey, Stefanie and Wittmann, Sabine and Irrgang, Pascal and Leicht, Natascha and Cordsmeier, Arne and Ensser, Armin and Rieker, Ralf J and Geppert, Carol and Sticht, Heinrich and Tenbusch, Matthias and Winkler, Thomas H and Gramberg, Thomas},
  title = {Live attenuated vaccination protects aged chimeric ACE2 mice from severe SARS-CoV-2 pathogenicity in vivo},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {4},
  pages = {e1014167},
  doi = {10.1371/journal.ppat.1014167}
}
Kostenlos starten →